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Abstract  84	  
 85	  
There is great interest in blood-based markers of Alzheimer’s disease, especially in 86	  
its pre-symptomatic stages. Therefore we aimed to identify plasma proteins whose 87	  
levels associate with potential markers of pre-symptomatic Alzheimer’s disease (AD). 88	  
We also aimed to characterise confounding by genetics and the effect of genetics on 89	  
blood proteins in general. Panel-based proteomics was performed using SOMAscan 90	  
on plasma samples from TwinsUK subjects who are asymptomatic for AD, 91	  
measuring the level of 1 129 proteins. Protein levels were compared to ten-year 92	  
change in CANTAB-Paired Associates Learning (PAL; n = 195), and regional brain 93	  
volumes (n = 34). Replication of proteins associated with regional brain volumes was 94	  
performed in 254 individuals from the AddNeuroMed (ANM) cohort. 95	  
 96	  
Across all the proteins measured genetic factors were found to explain ~26% of the 97	  
variability in blood protein levels on average. The plasma level of the Mitogen-98	  
Activated Protein Kinase (MAPK)-activated protein kinase 5 (MAPKAPK5) protein 99	  
was found to positively associate with the 10-year change in CANTAB-PAL in both 100	  
the individual and twin difference context. The plasma level of protein MAP2K4 was 101	  
found to suggestively associate negatively (Q < 0.1) with the volume of the left 102	  
entorhinal cortex. Future studies will be needed to assess the specificity of 103	  
MAPKAPK5 and MAP2K4 to eventual conversion to AD. 104	  
 105	  
 106	  
 107	  
 108	  
 109	  
 110	  
 111	  
1 - Background 112	  
 113	  
Currently no treatments exist that delay or prevent onset of Alzheimer’s disease 114	  
(AD). Studies using Magnetic Resonance Imaging (MRI) and Positron Emission 115	  
Tomography (PET) brain scans have revealed early signs of AD pathology in 116	  
subjects up to ~4 and ~17 years before the onset of dementia respectively [1]. 117	  
Pathological changes are likely to be least advanced in asymptomatic subjects, and 118	  
therefore potentially the most remediable in this group. This is the motivation behind 119	  
prevention trials in asymptomatic subjects with MRI or PET evidence of early AD 120	  
pathology [2]. 121	  
 122	  
However, such brain scans can be relatively expensive and require specialised 123	  
facilities. Therefore researchers are looking for surrogate markers that are relatively 124	  
inexpensive and non-invasive, yet informative enough for enrichment of prevention 125	  
trials. Preliminary results reviewed in [3-5] suggest that blood may be a useful source 126	  
of such markers. Despite this, only two discovery studies have been performed 127	  
comparing blood proteins to AD-related phenotypes exclusively in asymptomatic 128	  
individuals [6,7]. 129	  
 130	  
Recently, with the advent of panel-based proteomics, high-throughput studies are 131	  
becoming more feasible. One such approach, SOMAscan, allows >1 000 proteins to 132	  
be measured simultaneously and has already been applied in AD research [8-11]. 133	  
This approach has not yet been applied to discover blood markers of AD-related 134	  
phenotypes in asymptomatic individuals. 135	  
 136	  
While most blood protein biomarker studies have used cohorts of individuals, one 137	  
study of APOA1 blood DNA methylation and protein level has been performed using 138	  
24 twin-pairs discordant for episodic memory performance. Two APOA1 CpG sites 139	  
were found to associate with discordant episodic memory. However, the protein level 140	  
of APOA1 was not found to differ between discordant twins, possibly due to the small 141	  
sample size available [12].  142	  
 143	  
An advantage of studying ‘omics’ markers in twin cohorts is that it allows genetic and 144	  
environmental influences on markers and traits to be studied [13]. If the monozygotic 145	  
(MZ, i.e. ‘identical’) twin difference in the level of a marker associates with the twin 146	  
difference in trait value in twin-pairs, this suggests that the relationship between 147	  
marker and trait is not confounded by age, familial environment or genetics. 148	  
Confounding of AD blood biomarkers by age and/or genetics is a real possibility, as 149	  
these factors have been shown to affect both AD risk [14,15] and plasma protein 150	  
levels [16-18]. Despite this, twin differences have not yet been exploited in studies of 151	  
blood protein biomarkers of AD-related phenotypes.  152	  
 153	  
Genetic markers are generally more practical, robust and inexpensive to measure in 154	  
comparison to blood proteins. If the association between a blood protein and an AD-155	  
related phenotype is confounded by genetics then it is likely that a genetic test alone, 156	  
rather than a protein test, would prove more cost effective as a trial enrichment 157	  
biomarker. One reason to believe that genetic markers alone may not be optimal is 158	  
that it has been shown that that common variants, considered additively, explain only 159	  
24% - 33% of the total AD variation [19,20].  160	  
 161	  
In terms of cognitive tests, the Mini Mental State Examination (MMSE) is known to 162	  
not be very sensitive for detecting very early AD related changes in cognition. The 163	  
PAL task of the CANTAB cognition battery is thought to be more sensitive at this 164	  
stage. A 4-year study by de Jager et al [21] following healthy older adults has shown 165	  
that CANTAB-PAL, along with another test called the Graded Naming Test, 166	  
associates with significantly higher risk of conversion to Mild Cognitive Impairment 167	  
(MCI) or AD. However the rate of CANTAB-PAL decline, which may be more 168	  
informative, has not yet been evaluated in this context. It has also not yet been used 169	  
as an endophenotype in a blood biomarker study. In relation to age related cognitive 170	  
decline, Steves et al [22] have shown that a larger proportion of variance in 10-year 171	  
change in CANTAB-PAL total errors is explained by non-shared environment than by 172	  
additive genetics. A plasma protein biomarker measured in a single blood sample 173	  
could be more practical in some settings than cognitive testing over a ten-year period 174	  
in healthy older adults. 175	  
 176	  
In this study we use the TwinsUK and ANM SOMAscan datasets. First a heritability 177	  
analysis is performed, then the association between plasma proteins and AD 178	  
endophenotypes (10-year change in CANTAB-PAL and regional brain volumes) are 179	  
examined in asymptomatic individuals. 180	  
 181	  
2 - Materials and methods  182	  
 183	  
2.1 - Ethics statement 184	  
 185	  
Informed consent was obtained for all subjects according to the Declaration of 186	  
Helsinki (1991), and protocols and procedures were approved by the relevant local 187	  
ethical committees at each site. 188	  
 189	  
2.2 - Discovery cohort – TwinsUK 190	  
 191	  
Subjects used in this study were recruited from TwinsUK, a national register of adult 192	  
twins [23]. Full details of subject selection is given in Supplemental Methods. In brief, 193	  
a total of 212 subjects (106 twin pairs) were selected with longitudinal CANTAB-PAL 194	  
data (~1999 and ~2009) [22]. These subjects had also been assessed using MMSE 195	  
at the ~2009 visit. Fasted EDTA plasma samples, taken a median of around 16 196	  
months before CANTAB-PAL and MMSE testing (~2009), were used for proteomic 197	  
analysis, i.e. around 8 years after the ~1999 assessment. Given the high level of 198	  
missingness in APOE E4 genotype, and the small number of double APOE E4 199	  
carriers, we excluded double APOE E4 carriers from further analysis. Subjects who 200	  
were homozygous for the APOE E4 allele (10 individuals), or whose plasma sample 201	  
was haemolysed (6 individuals, determined by SomaLogic Inc) or failed SOMAscan 202	  
quality control (QC; 1 individual) were excluded leaving 195 subjects (93 twin-pairs 203	  
and 9 individuals). 204	  
 205	  
2.3 - Replication cohort – AddNeuroMed  206	  
 207	  
Subjects used in the replication study were individuals from the ANM cohort [24,25], 208	  
full details are given in Supplemental Methods and are summarised here. 254 209	  
subjects with both plasma SOMAscan and MRI baseline data, excluding subjects 210	  
homozygous for the APOE E4 allele (57 individuals), were available [9,10]. Baseline 211	  
EDTA plasma samples from fasted subjects were used, see Supplemental Table 1 212	  
for a comparison of the sample collection, processing and SOMAscan assay 213	  
between TwinsUK and ANM. Plasma samples were collected within a year and a half 214	  
of MMSE testing and MRI scanning. QC led to the exclusion of 7 subjects from ANM 215	  
(Supplemental Methods).  The remaining subjects were diagnosed as either 216	  
asymptomatic (control, N = 91), Mild Cognitive Impairment (MCI, N = 81) or AD (N = 217	  
82). 218	  
 219	  
2.4 - Proteomics 220	  
 221	  
SOMAscan methods and data for TwinsUK and ANM have been described 222	  
previously [18], but are described again in Supplemental Methods, and are briefly 223	  
summarised here. A single assay was used per plasma sample. All proteomics data 224	  
was transformed using the natural logarithm and transformed to zero mean and unit 225	  
standard deviation. Additionally, protein values >2.5 standard deviations from the 226	  
mean were excluded as outliers.  227	  
 228	  
2.5 – Magnetic Resonance Imaging 229	  
 230	  
Specifics of MRI pre-processing for each cohort are described below, due to 231	  
differences in methods all MRI data was logged and transformed to zero mean and 232	  
unit standard deviation to increase comparability. 233	  
 234	  
2.5.1 - TwinsUK 235	  
 236	  
TwinsUK MRI scans were performed approximately two years after plasma sampling 237	  
(median 805 days, Interquartile Range (IQR) 151 days). Volumes of the hippocampi 238	  
and the combined Brodman’s areas 28 and 34 (equivalent to the entorhinal cortex) in 239	  
the TwinsUK cohort were obtained from 38 subjects using Diffeomorphic Anatomical 240	  
Registration through Exponentiated Lie Algebra [26], Statistical Parametric Mapping 241	  
[27]  and MarsBar [28],  as fully described in Supplemental Methods.  242	  
 243	  
2.5.2 - AddNeuroMed 244	  
 245	  
Volumes of the hippocampi and entorhinal cortices in the ANM cohort were obtained 246	  
using FreeSurfer 5.1.0 from 276 ANM subjects who had undergone structural 247	  
magnetic resonance imaging (MRI). These regions were selected as they are known 248	  
to be related to early AD pathology, and were normalised by intracranial volume 249	  
(ICV) [29]. Detailed information about data acquisition, pre-processing, and QC 250	  
assessment have been described for this cohort in detail elsewhere [29-33]. 251	  
 252	  
2.6 - APOE genotyping 253	  
 254	  
Full details are given in Supplemental Methods, but in brief SNPs rs429358 and 255	  
rs7412 were determined from DNA samples using a TaqMan assay. 256	  
 257	  
2.7 - Statistical analysis 258	  
 259	  
A detailed account of the statistical methodology is provided in Supplementary 260	  
Methods 1, and is summarised here. All statistical analyses were performed in R 261	  
3.1.0, except for the transformation and 10-year change calculations for cognitive 262	  
scores which was performed in STATA 11 [22]. All double APOE e4 carriers were 263	  
excluded from analyses. Regressions in the discovery cohort were performed using 264	  
Generalised Estimation Equations (GEE) to account for twin dependencies [34,35]. 265	  
Subject age, gender, and recruitment centre were used as co-variates in all relevant 266	  
regressions. The Benjamini-Hochberg (i.e. False Discovery Rate) multiple testing 267	  
correction was used to generate Q-values with thresholds of Q < 0.05 used to 268	  
indicate association and Q < 0.1 to indicate suggestive association.  269	  
 270	  
Analysis of association between a protein level and 10-year change in CANTAB-PAL 271	  
in the twin difference context was performed by calculating twin differences in both, 272	  
and performing a linear regression between the two differences, covarying for twin-273	  
pair age. Twin modeling was performed using Structural Equation Modelling to 274	  
estimate the proportion of variance explained by additive genetics (A), shared 275	  
environment (C) and non-shared environment (E) [36]. 276	  
 277	  
3 - Results  278	  
 279	  
3.1 - Characteristics of the TwinsUK-SOMAscan subcohort 280	  
 281	  
Characteristics of the TwinsUK subjects with SOMAscan data are summarised in 282	  
Table 1. The MZ and dizygotic (DZ) twins are matched well, with the exception of 283	  
APOE missingness. Despite not being clinically diagnosed as cognitively impaired 284	  
there is variability in the cognitive ability of these subjects (MMSE range 23 - 30). 285	  
The subject with MMSE score of 23 was included as they showed no functional 286	  
deficit and did not affect the results of the following analyses (data not shown), all 287	  
other subjects MMSE score was greater than 25. 288	  
 289	  
3.2 - Heritability of plasma protein levels in TwinsUK 290	  
 291	  
Twin modeling was used to estimate the heritability of plasma proteins measured by 292	  
SOMAscan (Supplementary Table 2). The median proportion of variance of plasma 293	  
protein levels explained by additive genetics (A) was found to be 26% (IQR 3% - 294	  
46%). The proportion explained by total familial factors (additive genetics (A) or twins 295	  
shared environment (C)) was 34% (IQR 3% - 74%). Finally, a median of 54% (IQR 296	  
40% - 75%) of the variance in plasma protein levels was found to be explained by 297	  
non-shared environmental factors (E), including technical variability. The results were 298	  
comparable when a Van der Waerden transformation was used to overcome 299	  
deviations from the normal distribution (Supplementary Table 2).  300	  
 301	  
3.3 - Plasma protein markers of cognitive scores in asymptomatic individuals 302	  
from TwinsUK 303	  
 304	  
Levels of plasma proteins in TwinsUK subjects were first compared to MMSE scores, 305	  
both as a continuous and dichotomised variable. No protein was found to be 306	  
associated in either analysis (Supplementary Tables 4-5). 307	  
 308	  
No protein passed multiple testing corrections for association with CANTAB-PAL 309	  
total errors in 1999 or 2009, however MAPKAPK5 was found to be associated with 310	  
the 10-year change in CANTAB-PAL total errors (Figure 1a; β = 0.48, Q = 0.0059; 311	  
Supplementary Tables 5 - 7). 312	  
 313	  
In total 54 MZ twin pairs had complete data on plasma MAPKAPK5 levels and 10-314	  
year change in CANTAB-PAL total errors. Within these subjects MAPKAPK5 was 315	  
found to associate with 10-year change in CANTAB-PAL total errors in the context of 316	  
MZ-pair differences (Figure 1b; β = 0.55, p = 0.030). In a twin model non-shared 317	  
environmental factors (E) were found to explain 90% (95% confidence Interval (CI): 318	  
64 – 100%) of the variance in the plasma level of MAPKAPK5 when a Van der 319	  
Waerden transformation was applied (A = 10% (CI: 0 – 36%), C = 0% (CI: 0 – 23%), 320	  
E = 90% (CI: 64 – 100%); Supplementary Table 1). 321	  
 322	  
3.4 - Plasma protein markers of MRI measures in asymptomatic individuals 323	  
from TwinsUK 324	  
 325	  
Plasma protein levels were then compared to selected regional brain volumes 326	  
derived from structural MRI scans, taking into account age and twin relatedness 327	  
(Supplementary Tables 8-11). These selected regions of interest – the left and right 328	  
hippocampus (LH and RH respectively) and entorhinal cortices (LE and RE 329	  
respectively)  - are known to show early pathology and greater atrophy in Alzheimer’s 330	  
disease [1,37].  331	  
 332	  
Full results are given in Supplemental Tables 8-11. The plasma level of one protein – 333	  
FAM107B - was found to associate with the volume of both the left (β = 1.05, Q = 334	  
0.034) and right (β = 0.77, Q = 0.015) entorhinal cortices. Two proteins associated 335	  
with the volume of one region (Q < 0.05) were also associated with the volume of 336	  
three out of four regions at a suggestive threshold of Q < 0.1, NSF1C (positively with 337	  
LH, LE and RE) and MAP2K4 (negatively with RH, LE and RE; Supplementary 338	  
Tables 8 - 11). The association between MAP2K4 and left entorhinal cortex volume 339	  
in TwinsUK is shown in Figure 2a.  340	  
 341	  
Of the three proteins most consistently associated with multiple brain regions – 342	  
FAM107B, NSF1C and MAP2K4 – only MAP2K4 was also found to be nominally 343	  
associated with the 10-year change in CANTAB-PAL total errors, (rank = 16th, β = -344	  
0.24, p-value = 0.026, Q = ~1.0; Supplementary Table 7). Similarly, MAPKAPK5 was 345	  
nominally associated with the volume of the RH (rank = 93rd, β = -0.28, p-value = 346	  
0.039, Q = 0.48; Supplementary Table 6). 347	  
 348	  
3.5 - Replication of discovery results in AddNeuroMed 349	  
 350	  
We wished to replicate the association of plasma levels of the proteins FAM107B, 351	  
NSF1C and MP2K4 with MRI regional volumes in the ANM SOMAscan data. 352	  
However, as TwinsUK consists of asymptomatic females, whereas ANM also 353	  
includes males and cognitively impaired individuals, we wished to see if this had any 354	  
impact on replication. We therefore performed the replication analysis in ANM in all 355	  
subjects, in just the asymptomatic (control) subjects and in just the asymptomatic 356	  
females separately. The characteristics of the relevant ANM subcohorts are given in 357	  
Table 2. 358	  
 359	  
The plasma level of the protein MAP2K4 in asymptomatic female ANM subjects was 360	  
found to suggestively associate with the volume of the LE (β = -0.64, p = 0.0025, Q = 361	  
0.088), in a direction consistent with the discovery cohort (Figure 1). While this trend 362	  
is visible in Figure 2b, there is a possible outlier remaining in the dataset (with the 363	  
lowest volume and highest protein level). Removing this possible outlier reduces the 364	  
significance but does not remove the association of MAP2K4 with the volume of the 365	  
LE in asymptomatic females (β = -0.54, p = 0.014). 366	  
 367	  
No other combination of proteins, subjects or regions showed an association 368	  
(Supplementary Table 12). However, the directions of association were consistent for 369	  
all the proteins between asymptomatic females from ANM and TwinsUK, and the 370	  
models including these proteins appeared to explain a higher proportion of the 371	  
variance (R2) in asymptomatic females versus the other subject groups. 372	  
 373	  
Twin models suggest that plasma levels of MAP2K4 may be more affected by 374	  
additive genetics than by environmental influences (A = 72% (CI: 15 – 83%), C = 0% 375	  
(CI: 0 – 55%), E = 28% (CI: 17 – 39%); Supplementary Table 1). 376	  
 377	  
4 - Discussion  378	  
 379	  
In this study we have applied the following methodologies to the study of blood 380	  
protein biomarkers of AD endophenotypes for the first time: (1) the use of panel-381	  
based proteomics in an asymptomatic cohort, (2) the use of CANTAB-PAL as an 382	  
endophenotype and (3) the use of twin samples. We also believe this is the third 383	  
discovery study of blood protein markers of AD endophenotypes in asymptomatic 384	  
individuals, and the largest twin high-throughput proteomics study performed to date. 385	  
 386	  
We are only aware of one other study estimating the heritability of blood protein 387	  
levels in a high-throughput manner [17]. The estimates from our study suggest a 388	  
heritability that is at least twice as high on average, further demonstrating the 389	  
potential for genetic confounding of blood protein biomarkers. 390	  
 391	  
The suggestive/nominal replication of MAP2K4 in ANM, again in asymptomatic 392	  
individuals, is consistent with the hypothesis that it shows the greatest variability in 393	  
the asymptomatic phase of AD, which is what is required of an early biomarker. This 394	  
may be why it has not been reported in previous AD blood biomarker studies, which 395	  
have mostly focused on later disease stages. As well as being negatively associated 396	  
with entorhinal cortex volume, MAP2K4 has been linked to phosphorylation of tau 397	  
[38] and of amyloid precursor protein through JNK [39]. In both cases these 398	  
phosphorylation events are believed to lead to increased AD pathology. 399	  
 400	  
MAPKAPK5 has mostly been studied in the context of cancer [40] and rheumatoid 401	  
arthritis [41], and to the best of our knowledge has not previously been implicated in 402	  
AD. However, it is interesting that we find two different MAPKs whose level in plasma 403	  
associates with AD endophenotypes. 404	  
 405	  
The use of longitudinal change in CANTAB-PAL, a cognitive test that is sensitive to 406	  
early cognitive decline, was critical in the discovery of MAPKAPK5 as a potential 407	  
biomarker relevant to AD. This demonstrates the importance of studying decline in 408	  
cognitive abilities using sensitive tests in asymptomatic older adults.  409	  
 410	  
By showing an association between MAPKAPK5 and 10-year change in CANTAB-411	  
PAL total errors in the MZ twin difference context, we have demonstrated that the 412	  
association of MAPKAPK5 and change in cognitive ability in older adults is 413	  
independent of genetic and twin-shared environmental factors.  This is consistent 414	  
with twin modeling which suggests that plasma MAPKAPK5 levels are mostly 415	  
affected by non-shared environmental factors. This has also been demonstrated for 416	  
10-year change in CANTAB-PAL total errors in a previous study [22]. Genetic risk, 417	  
and many aspects of twin-shared environment (such as maternal and family factors) 418	  
have been implicated in cognitive ageing and dementia, but are currently not 419	  
modifiable.  Given our findings we hypothesise that MAPKAPK5 may be a biomarker 420	  
of modifiable cognitive ageing. Selection of individuals for intervention studies whose 421	  
risk is modifiable may lead to improved outcomes.  422	  
 423	  
The failed replication of findings for proteins FAM107B and NSFL1C may indicate 424	  
that the original findings are false positives, or they may indicate failed replication 425	  
due to the technical differences or small sample sizes present in this study.  426	  
However, in asymptomatic females of the replication cohort, the directions of 427	  
association of all of the proteins were consistent with discovery findings. Additionally, 428	  
the proportion of variance explained by the models was largest in the asymptomatic 429	  
females. This is consistent with a failure of replication due to small sample size and 430	  
therefore insufficient statistical power. This suggests that the sample size of this 431	  
replication cohort may have been a limitation. 432	  
 433	  
There is great demand for inexpensive and relatively non-invasive markers that could 434	  
be used to identify asymptomatic subjects at risk of AD to recruit into prevention 435	  
trials. In this study we started by demonstrating heritability of plasma protein levels, 436	  
which raise the potential of genetic confounding of plasma protein biomarkers of 437	  
disease. We then looked for plasma proteins biomarkers of AD endophenotypes in 438	  
asymptomatic twins. The plasma protein level of two mitogen activated protein 439	  
kinases – MAP2K4 and MAPKAPK5 - were identified as possible biomarkers of early 440	  
AD. MAPKAPK5 was shown to be associated with decline in cognitive ability in the 441	  
context of MZ twin differences. This suggests that it conveys information on cognitive 442	  
ability that is complementary to genetic markers, and may be a biomarker of 443	  
modifiable cognitive ageing. Future studies will need to assess the specificity of 444	  
MAPKAPK5 and MAP2K4 to eventual AD, and their potential utility as enrichment 445	  
biomarkers for clinical trials. 446	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a). 641	  
 642	  
b). 643	  
 644	  
Figure 1 – The relationship between plasma MAPKAPK5 levels and 10-year change 645	  
in CANTAB-PAL in TwinsUK. Scatterplot comparing (a) plasma MAPKAPK5 levels 646	  
and 10-year change in CANTAB-PAL in TwinsUK, or (b) MZ twin differences in both. 647	  
Points are coloured by APOE e4 data. (a) GEEs covarying for age and taking into 648	  
account twin relatedness show an association between plasma MAPKAPK5 and the 649	  
10-year change in CANTAB-PAL (β = 0.48, Q = 0.0059). (b) Linear regression co-650	  
varying for age shows an association between plasma MAPKAPK5 and the 10-year 651	  
change in CANTAB-PAL in the MZ twin difference context (β = 0.55, p = 0.030). 652	  
 653	  
a). 654	  
 655	  
b). 656	  
 657	  
Figure 2 – The association between plasma MAP2K4 levels and (a) left 658	  
parahippocampal volume in TwinsUK or (b) left entorhinal cortex volume in ANM. 659	  
Scatterplot comparing plasma MAP2K4 levels with the volume of the left entorhinal 660	  
cortex are given for the two cohorts. Points are coloured by APOE e4 data, and 661	  
whether they appear to be outliers. (a) GEEs covarying for age and taking into 662	  
account twin relatedness show a suggestive association (Q < 0.1) between plasma 663	  
MAP2K4 and the volume of the left entorhinal cortex in TwinsUK. (b) Linear 664	  
regression co-varying for age and centre shows a suggestive association (Q < 0.1) 665	  
between plasma MAP2K4 and the volume of the left entorhinal cortex in ANM when 666	  
a possible outlier (in blue) is included (β = -0.64, p = 0.0025, Q = 0.088), or nominal 667	  
association (p < 0.05) when it is excluded (β = -0.54, p = 0.014). 668	  
 669	  
 670	  
 671	  
 672	  
 673	  
 674	  
 675	  
Table 1 – Characteristics of the discovery cohort (TwinsUK) with SOMAscan data. 676	  
Double APOE E4 carriers were excluded from this study. 677	  
 
Monozygotic 
subjects 
Dizygotic 
subjects 
Subjects without 
twin-pair data 
Number of subjects 110 (55 pairs) 
76 (38 
pairs) 
9 
Number of MRI 
scan subjects 
34 0 2 
Age (median [IQR])] 65 [9.1] 63 [8.6] 67 [11] 
% Female 100 100 100 
APOE4 (# alleles 
0/1 {NA})  
44/18 {48} 61/9 {6} 8/0 {1} 
MMSE (median 
[IQR] {# NA}) 
29 [1] {7} 29 [1] {2} 28 [3] 
 678	  
 679	  
 680	  
 681	  
 682	  
 683	  
 684	  
 685	  
 686	  
 687	  
 688	  
 689	  
Table 2 – Characteristics of the replication cohort (ANM) with complete SOMAscan 690	  
and MRI data. Double APOE E4 carriers were excluded from this study. 691	  
 All 
Controls 
only 
Female 
controls only 
Number of subjects 254 91 51 
% Female 100% 100% 100% 
Median age 74 72 72 
IQR age 8 8.5 8.5 
APOE4 (# alleles 0/1 
{NA}) 
158/90 {6} 66/24 {1} 35/15 {1} 
Diagnostic groups 
(Control/MCI/AD) 
91/81/82 91/./. 51/./. 
Median MMSE by 
diagnostic group 
(Control/MCI/AD) 
29/28/22 29/./. 30/./. 
IQR MMSE CTL 1/3/7.5 1/./. 1/./. 
 692	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 695	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 699	  
 700	  
 701	  
Supplementary Table 1 – Differences in plasma sampling, processing and 702	  
SOMAscan assays between TwinsUK and ANM. Important sampling and processing 703	  
variables are listed in line with the recommendations of the Blood-Based Biomarker 704	  
Interest Group (BBBIG) and the STandards for Alzheimer's Research in Blood 705	  
biomarkers group (STAR-B) O’Bryant et al (Ahead of print; Alzheimer’s & Dementia). 706	  
Consistent steps include the use of fasted subjects, 21G or 23G needles depending 707	  
on vein size, purple topped EDTA tubes, and approximately two hours from blood 708	  
draw to samples freezing. Additionally the SOMAscan assay was performed on 709	  
ANM, DCR and ARUK samples together, but separately for TwinsUK. RT = Room 710	  
Temperature. 711	  
 712	  
Supplementary Table 2 – Twin modeling results for plasma protein levels in 713	  
TwinsUK. Twin models in OpenMX were applied to estimate the proportion of 714	  
variance explained by (A) additive genetics, (C) shared environment and (E) non-715	  
shared environment. A cross reference between analytes and a review of blood 716	  
based protein markers of AD-related phenotypes is given [5]. Twin modelling 717	  
performed on pre-processed SOMAscan data, and also on SOMAscan data after a 718	  
Van der Waerden normalisation which normalises data. Shapiro-Wilks tests 719	  
performed on SOMAscan data to indicate deviations from normal distribution. 720	  
 721	  
Supplementary Table 3 – Results from regressions of plasma proteins against 722	  
MMSE score in TwinsUK. Regressions performed using GEE to account for twin 723	  
dependancies, with age as a covariate. 724	  
 725	  
Supplementary Table 4 – Results from regressions of plasma proteins against 726	  
dichotomized MMSE score (29-30 vs 23-28) in TwinsUK. Regressions performed 727	  
using GEE to account for twin dependancies, with age as a covariate. 728	  
 729	  
Supplementary Table 5 – Results from regressions of plasma proteins against 730	  
square root of CANTAB-PAL total errors from ~1999 in TwinsUK. Regressions 731	  
performed using GEE to account for twin dependancies, with age as a covariate. 732	  
 733	  
Supplementary Table 6 – Results from regressions of plasma proteins against 734	  
square root of CANTAB-PAL total errors from ~2009 in TwinsUK. Regressions 735	  
performed using GEE to account for twin dependancies, with age as a covariate. 736	  
 737	  
Supplementary Table 7 – Results from regressions of plasma proteins against 10-738	  
year change in CANTAB-PAL total errors in TwinsUK. Regressions performed using 739	  
GEE to account for twin dependancies, with age as a covariate. 10-year change in 740	  
CANTAB-PAL adjusted to take into account baseline score in a linear regression. 741	  
 742	  
Supplementary Table 8 – Results from regressions of plasma proteins against the 743	  
volume of the left hippocampus in TwinsUK. Regressions performed using GEE to 744	  
account for twin dependancies, with age as a covariate. 745	  
 746	  
Supplementary Table 9 – Results from regressions of plasma proteins against the 747	  
volume of the right hippocampus in TwinsUK. Regressions performed using GEE to 748	  
account for twin dependancies, with age as a covariate. 749	  
 750	  
Supplementary Table 10 – Results from regressions of plasma proteins against the 751	  
volume of the left entorhinal cortex in TwinsUK. Regressions performed using GEE 752	  
to account for twin dependancies, with age as a covariate. 753	  
 754	  
Supplementary Table 11 – Results from regressions of plasma proteins against the 755	  
volume of the right entorhinal cortex in TwinsUK. Regressions performed using GEE 756	  
to account for twin dependancies, with age as a covariate. 757	  
 758	  
Supplementary Table 12 – Results of replication study of plasma protein markers of 759	  
regional brain volumes in AddNeuroMed. Regressions performed using linear 760	  
regression, taking into account age, gender and recruitment centre as appropriate. 761	  
The plasma levels of FAM107B, NSFL1C and MAP2K4 are compared to regional 762	  
brain volumes in ANM. Three subsets of the ANM cohort with relevant data were 763	  
used: All = all subjects, Ctl = only symptomatic individuals (i.e. controls), and Both = 764	  
only asymptomatic females. LH = Left Hippocampus, RH = Right Hippocampus, LE = 765	  
Left Entorhinal cortex and RE = Right Entorhinal cortex. 766	  
 767	  
Supplementary Methods 768	  
 769	  
1 - Discovery cohort – TwinsUK 770	  
 771	  
Subjects used in this study were recruited from TwinsUK, a national register of adult 772	  
twins [23]. Specifically, a subset of the subjects from a previous study of cognitive 773	  
ability were used [22]. A total of 212 subjects (106 twin pairs) were selected: all of the 774	  
monozygotic twin-pairs and a random selection of the dizygotic twin-pairs (chosen by 775	  
R function ‘sample’) from the cohort of 324 TwinsUK subjects with longitudinal 776	  
CANTAB-PAL data (~1999 and ~2009) [22]. These subjects had also been assessed 777	  
using MMSE at the ~2009 visit. Fasted EDTA plasma samples, taken a median of a 778	  
year and four months (median 488 days, interquartile range (IQR) of 568 days) 779	  
before CANTAB-PAL and MMSE testing (~2009), were used for proteomic analysis. 780	  
See Supplementary Table 1 for technical details of blood sampling and processing. 781	  
Subjects who were homozygous for the APOE E4 allele (10 individuals), or whose 782	  
plasma sample was haemolysed (6 individuals) or failed SOMAscan quality control 783	  
(QC; 1 individual) were excluded leaving 195 subjects (93 twin-pairs and 9 784	  
individuals). 785	  
 786	  
2 - Replication cohort – AddNeuroMed  787	  
 788	  
Subjects used in the replication study were individuals from the ANM cohort [24,25]. 789	  
274 subjects with both plasma SOMAscan and MRI baseline data were available 790	  
[8,9]. Subject homozygous for the APOE E4 allele were excluded, leaving a total of 791	  
254 individuals. Baseline EDTA plasma samples from fasted subjects were used, 792	  
see Supplemental Table 1 for a comparison of the sample collection, processing and 793	  
SOMAscan assay between TwinsUK and ANM. Plasma samples were collected 794	  
within a year and a half of MMSE testing and MRI scanning. All subjects were 795	  
assessed with a standardized assessment protocol including an informant interview 796	  
for diagnosis and cognitive assessment such as the MMSE, which has been 797	  
described previously [24,25]. Subjects were diagnosed as either asymptomatic 798	  
(control, N = 91), Mild Cognitive Impairment (MCI, N = 81) or AD (N = 82) based on 799	  
National Institute of Neurological and Communicative Disorders and Stroke and the 800	  
Alzheimer’s Disease and Related Disorders Association (NINCDS- ADRDA) criteria. 801	  
 802	  
3 - Proteomics 803	  
 804	  
SOMAscan methods and data for TwinsUK and ANM have been described 805	  
previously [18], but are described again briefly here. Proteins were measured using a 806	  
SOMAmer-based capture array called ‘SOMAscan’ (SomaLogic, Inc, Boulder, 807	  
Colorado). For more details on the assay see Gold et al [11] and the SomaLogic Inc 808	  
website (http://www.somalogic.com/Products-Services/SOMAscan/FAQs.aspx).  809	  
 810	  
A single assay was used per plasma sample, i.e. no technical replicates were 811	  
performed. TwinsUK proteomic data was collected using SOMAscan version 3 on 65 812	  
µl of plasma, measuring 1,129 proteins, whereas ANM+ARUK+DCR proteomic data 813	  
was collected using SOMAscan version 2 on 8 µl of plasma, measuring 1,001 814	  
proteins. All except 21 of the proteins measured by SOMAscan v2 are also 815	  
measured by SOMAscan v3. TwinsUK proteomics data are publicly available upon 816	  
request on the department website (http://www.twinsuk.ac.uk/data-817	  
access/accessmanagement/). We aim to make the ANM+ARUK+DCR data available 818	  
to the public as soon as possible. In the short term the authors can be contacted and 819	  
collaborations established under an agreement shared with SomaLogic. 820	  
 821	  
SomaLogic’s standard QC and normalization processes were applied [18]. Data from 822	  
one sample from the TwinsUK cohort failed SomaLogic’s QC procedures and so was 823	  
excluded. Six additional TwinsUK samples (two from subjects who had undergone 824	  
MRI scans) appeared to be haemolysed, and so were excluded. No Principal 825	  
Component Analysis (PCA) outliers were identified for the TwinsUK SOMAscan data, 826	  
whereas 7 PCA outliers from the ANM+ARUK+DCR SOMAscan data were identified 827	  
and excluded. All proteomics data was transformed using the natural logarithm and 828	  
transformed to zero mean and unit standard deviation SD. Additionally, protein 829	  
values >2.5 SD from the mean were excluded as outliers. This cutoff was chosen as 830	  
a lower cutoff produced low p-values for some proteins which appeared to be driven 831	  
by outliers. 832	  
 833	  
4 – TwinsUK Magnetic Resonance Imaging 834	  
 835	  
TwinsUK MRI scans were performed approximately two years after plasma sampling 836	  
and MMSE testing (median 805 days, IQR 151 days). Volumes of the hippocampi 837	  
and the combined Brodman’s areas 28 and 34 (equivalent to the entorhinal cortex) in 838	  
the TwinsUK cohort were obtained from 38 subjects using the Diffeomorphic 839	  
Anatomical Registration through Exponentiated Lie Algebra (DARTEL) technique 840	  
[26]. This method produces a template based on this population of older female 841	  
brains leading to improved registration. Structural processing was performed using 842	  
Statistical Parametric Mapping (SPM8) software 843	  
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8). The structural magnetic resonance 844	  
images were converted to axial slices and origins of all images reset to the anterior 845	  
commissure, prior to segmentation using the standard unified segmentation model in 846	  
SPM8 [27]. Then, Grey Matter (GM) population templates were generated from the 847	  
entire image dataset using the DARTEL technique [26]. After an initial affine 848	  
registration of the GM DARTEL templates to the tissue probability maps in Montreal 849	  
Neurological Institute (MNI) space (http://www.mni.mcgill.ca/), non-linear warping of 850	  
GM images was performed to the DARTEL GM template in MNI space with a 1.5mm 851	  
cubic resolution. The GM volume (GMV) at each voxel was obtained through 852	  
modulation.  Finally, the GMV images were smoothed with Gaussian kernel with a 853	  
Full-Width at Half-Maximum of 8mm. After spatial pre-processing, GMV for the 854	  
regions of interest were extracted from the smoothed, modulated and normalized 855	  
images using MarsBar software [28]. 856	  
 857	  
5 - APOE genotyping 858	  
 859	  
DNA was extracted from whole blood samples from TwinsUK samples using Nucleon 860	  
BACC3 Genomic DNA Extraction Kits (GE Healthcare, Buckinghamshire). DNA was 861	  
extracted from blood leukocytes from ANM samples by a standard phenol-chloroform 862	  
extraction.  The SNPs rs429358 and rs7412 were determined by allelic discrimination 863	  
assays based on fluorogenic 59 nuclease activity, and the alleles inferred. APOE 864	  
data for subjects with ambiguous genotypes were treated as missing. TaqMan SNP 865	  
genotyping assays were performed on an ABI Prism 7900HT and analyzed using 866	  
SDS software, according to the manufacturer’s instructions (Applied Biosystems, 867	  
Warrington, UK).  868	  
 869	  
6 - Statistical analysis 870	  
 871	  
All statistical analyses were performed in R 3.1.0, except for the transformation and 872	  
10-year change calculations for cognitive scores. All double APOE e4 carriers were 873	  
excluded from analyses, as too few were present in the discovery cohort to make 874	  
inclusion as a co-variate viable. Regressions in the discovery cohort were performed 875	  
using Generalised Estimation Equations (GEE), allowing twin dependencies to be 876	  
accounted for as clusters with exchangeable correlation structures [34,35]. GEE 877	  
analysis was performed using the ‘geepack’ package. For MMSE, due to skewness, 878	  
GEE was also performed against dichotomised MMSE scores (29-30 vs 23-28). 879	  
Linear regressions were performed using the ‘lm’ command. Subject age, gender, 880	  
and recruitment centre were used as co-variates in all regressions, except in 881	  
TwinsUK were a single centre was used, and the female only subcohort analyses 882	  
where gender was not relevant. Skewness was calculated using the ‘e1071’ 883	  
package. The Benjamini-Hochberg (i.e. False Discovery Rate) multiple testing 884	  
correction was used to generate Q-values using ‘p.adjust’, with thresholds of Q < 885	  
0.05 used to indicate association and Q < 0.1 to indicate suggestive association. All 886	  
SOMAscan analyses were performed using all proteins, except replication and twin 887	  
difference analyses, which focused on candidates to increase statistical power. 888	  
 889	  
Analysis of association between a protein level and 10-year change in CANTAB-PAL 890	  
in the MZ-twin difference context was performed by calculating twin differences in 891	  
both, and performing a linear regression between the two differences, covarying for 892	  
twin-pair age. 893	  
 894	  
Twin modeling was performed using Structural Equation Modelling in OpenMX [36] in 895	  
R to estimate the proportion of variance explained by additive genetics (A), shared 896	  
environment (C) and non-shared environment (E). This was performed on the 897	  
SOMAscan data, both untransformed, and transformed using the Van der Waerden 898	  
transformation (script provided by Maciej Trzaskowski). 899	  
 900	  
STATA 11 was used for square root transformation of CANTAB-PAL total errors, and 901	  
to calculate the 10-year change in CANTAB-PAL total errors as described in Steves 902	  
et al [22]. It was also used to calculate 10-year change  as a residual of a linear 903	  
model, co-varying for baseline score [22]. 904	  
 905	  
